A. Girvan

发表

Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life – A Case Study of the Innovative Medicines Initiative

J. Johnston, K. Abrams, M. Happich, 2020, Clinical pharmacology and therapeutics.

Inhibition of DNA Replication and Induction of S Phase Cell Cycle Arrest by G-rich Oligonucleotides*

W. Mcgregor, P. Bates, J. Trent, 2001, The Journal of Biological Chemistry.

Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study.

E. Smit, P. Schnabel, J. Aerts, 2015, Lung cancer.

Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.

E. Van Cutsem, R. Walgren, Li‐Tzong Chen, 2020 .

Relationship between change in α-fetoprotein (AFP) and patient (pt) survival in hepatocellular carcinoma (HCC): A real-world electronic medical records (EMR) database study.

T. Sugihara, P. Abada, Y. Fang, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

K. Pradhan, A. Verma, U. Steidl, 2019, Clinical Cancer Research.

Physician- and patient-reported symptom concordance and association with quality of life in hepatocellular carcinoma.

J. Piercy, A. Leith, M. Jen, 2022, Future oncology.

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH).

P. Galle, J. Llovet, A. Zhu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin

Paula J. Bates, Mark W. Ball, W. Pierce, 2006, Molecular Cancer Therapeutics.

AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin.

W. Pierce, P. Bates, Y. Teng, 2007, Cancer research.

Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA

J. Ivanova, M. Lahn, E. Hayes-Larson, 2015, Drugs in context.

Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV

C. Obasaju, M. Socinski, R. Govindan, 2009, Clinical lung cancer.

Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.

E. Van Cutsem, Jiangang Liu, R. Walgren, 2021, The Lancet. Oncology.

Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials

M. Kudo, D. Cella, P. Galle, 2020, ESMO Open.

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.

Joon-Oh Park, P. Malfertheiner, M. Kudo, 2017, European journal of cancer.

Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.

E. Smit, P. Schnabel, J. Aerts, 2015, Lung cancer.

AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin.

Mark W. Ball, W. Pierce, J. Klein, 2006, Molecular cancer therapeutics.

Prospective observational comparison of clinical outcomes between african-american and caucasian patients receiving second-line treatment with pemetrexed for advanced non-small-cell lung cancer.

C. Obasaju, E. Stepanski, A. Adjei, 2013, Clinical lung cancer.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study.

E. Smit, J. Aerts, D. Moro-Sibilot, 2016, Lung cancer.

Prospective observational comparison of clinical outcomes between african-american and caucasian patients receiving second-line treatment with pemetrexed for advanced non-small-cell lung cancer.

C. Obasaju, E. Stepanski, A. Adjei, 2013, Clinical lung cancer.

Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study

M. Boeri, J. Poon, N. Parikh, 2023, BMC Cancer.

Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME).

E. Smit, P. Schnabel, J. Aerts, 2012, Lung cancer.